Drug
Vctx210a Unit
Vctx210a Unit: highest development phase Phase 1, developed by CRISPR Therapeutics. 1 trial record tracked on RxWires.
- Highest phase
- Phase 1
- Developer
- CRISPR Therapeutics
Trials
| Drug | Phase | Indication |
|---|---|---|
| VCTX210A unit NCT05210530 | Phase 1 | Diabetes Mellitus |
Latest
No recent events.
Follow Vctx210a Unit on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.